Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439867 · ClinicalTrials.gov registry record · Phase 2
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01439867 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 18 participants.
The verdict
NCT01439867, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective was to characterize corrected serum calcium levels on treatment with cinacalcet in pediatric patients with secondary hyperparathyroidism (HPT).
Interventions
- DRUG Standard of Care
- DRUG Cinacalcet hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-06-22 |
| Est. Completion | 2016-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439867
The ClinicalTrials.gov registry entry for NCT01439867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01439867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439867 about?
NCT01439867 is a clinical study titled "Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism". The primary objective was to characterize corrected serum calcium levels on treatment with cinacalcet in pediatric patients with secondary hyperparathyroidism (HPT).
What is the current status of trial NCT01439867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-06-22. Estimated completion is 2016-06-03.
What interventions are being tested in trial NCT01439867?
The interventions under investigation include: Standard of Care (DRUG), Cinacalcet hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01439867?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.